Abbott
-
Report: Pathologist says Abbott’s rapid Covid-19 test produces 15% false-negative rate
NPR reported on the study by The Cleveland Clinic’s Dr. Gary Procop, which has not been peer reviewed. Procop acknowledged that he had stored samples in a special solution not recommended by the company, which defended the ID NOW test.
-
How medtech companies are fighting Covid-19?
In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing […]
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Abbott gets emergency use authorization for rapid Covid-19 test
The diagnostics company said it had received the EUA for use of its ID NOW system, which can detect a positive result in as low as five minutes and a negative result in 13 minutes. ID NOW is mainly used in urgent care settings.
-
Beset by lawsuits, criticism in U.S., opioid makers eye new market In India
American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.
-
Dexcom, glowing from fabulous results, dismisses Medtronic as a viable CGM competitor at JPM
Dexcom’s executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
-
Dexcom shares take a hit as Abbott’s CGM system gets CMS nod
A sooner-than-expected availability of a rival’s continuous glucose monitoring system to Medicare patients sends Dexcom’s stocks lower, but an analyst believes this will be temporary.
-
FDA approves Abbott’s continuous glucose monitoring system, moving beyond painful finger pricks
Although DexCom actually was the first to get FDA approval for a continuous glucose monitor with its G5 model last year, it requires finger sticks to calibrate the device.
-
Chicago’s $69.7 billion healthcare industry makes it a hub for innovation
In a new report, the Health Care Council of Chicago, an initiative of Matter and Leavitt Partners, outlined the current status of Chicago’s healthcare ecosystem.
-
Devices & Diagnostics, Diagnostics
Abbott, DOD collaborate on concussion blood test
Assessing mild traumatic brain injury with a blood test could be tremendously useful for the military. More than 360,000 service members have suffered a TBI since 2000, and diagnosing them has often been inexact
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Analysts are bullish on Abbott’s St. Jude Medical deal, but …
Abbott has swallowed up St. Jude Medical for $25 billion and while analysts find the deal to be a positive one, historically large M&As rarely pan out.
-
Vanishing stent vs durable stent wars continue
Abbott Vascular’s Absorb bioresorbable stent that disappears into the body over time seems to be coming up short compared with the company’s durable drug-eluting stent, Xience.
-
J&J’s $4.32B Abbott Medical Optics deal bolsters eye surgery business
The deal is a win-win for both companies.
-
Hospitals, Devices & Diagnostics
Abbott’s Absorb is “holy grail” in coronary stents but…
Abbott’s Absorb is a long-awaited, much-hyped technology to battle coronary artery disease, but its immediate success is not guaranteed.
-
Bioresorbable heart stent wars to heat up in U.S.
FDA approves Absorb, first fully bioresorbable polymer stent, which will heat up competition with Boston Scientific’s partially absorbable version.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
